Functional Characterisation of Alpha-Galactosidase A Mutations as a Basis for a New Classification System in Fabry Disease

English version České info

Fabry disease (FD) is an X-linked hereditary defect of glycosphingolipid storage caused by mutations in the gene encoding the lysosomal hydrolase α-galactosidase A (GLA, α-gal A). To date, over 400 mutations causing amino acid substitutions have been described. Most of these mutations are related to the classical Fabry phenotype. Generally in lysosomal storage disorders a reliable genotype/phenotype correlation is difficult to achieve, especially in FD with its X-linked mode of inheritance. In order to predict the metabolic consequence of a given mutation, we combined in vitro enzyme activity with in vivo biomarker data. Furthermore, we used the pharmacological chaperone (PC) 1-deoxygalactonojirimycin (DGJ) as a tool to analyse the influence of individual mutations on subcellular organelle-trafficking and stability. We analysed a significant number of mutations and correlated the obtained properties to the clinical manifestation related to the mutation in order to improve our knowledge of the identity of functional relevant amino acids. Additionally, we illustrate the consequences of different mutations on plasma lyso-globotriaosylsphingosine (lyso-Gb3) accumulation in the patients' plasma, a biomarker proven to reflect the impaired substrate clearance caused by specific mutations. The established system enables us to provide information for the clinical relevance of PC therapy for a given mutant. Finally, in order to generate reliable predictions of mutant GLA defects we compared the different data sets to reveal the most coherent system to reflect the clinical situation.

Vyšlo v časopise: Functional Characterisation of Alpha-Galactosidase A Mutations as a Basis for a New Classification System in Fabry Disease. PLoS Genet 9(8): e32767. doi:10.1371/journal.pgen.1003632
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003632

Souhrn

Zdroje

1. SpadaM, PagliardiniS, YasudaM, TukelT, ThiagarajanG, et al. (2006) High incidence of Later-Onset Fabry Disease Revealed by Newborn Screening. Am J Hum Genet 79 : 31–40.

2. WittmannJ, KargE, TuriS, LegniniE, WittmannG, et al. (2012) Newborn Screening for Lysosomal Storage Disorders in Hungary. JIMD Rep 6 : 117–125.

3. IshiiS, ChangHH, KawasakiK, YasudaK, WuHL, et al. (2007) Mutant α-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. Biochem J 406(Pt 2): 285–295.

4. KotankoP, KramarR, DevrnjaD, PaschkeE, VoigtländerT, et al. (2004) Results of a Nationwide Screening for Anderson-Fabry Disease among Dialysis Patients. J Am Soc Nephrol 15 : 1323–1329.

5. MehtaA, BeckM, EyskensF, FelicianiC, KantolaI, et al. (2010) Fabry disease: a review of current management strategies. QJM 103 : 641–59.

6. RolfsA, BoettcherT, ZschiescheM, MorrisP, WinchesterB, et al. (2005) Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 3661794–6.

7. NakaoS, TakenakaT, MaedaM, KodamaC, TanakaA, et al. (1995) An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 3;333 : 288–93.

8. KaseR, BierfreundU, KleinA, KolterT, UtsumiK, et al. (2000) Characterization of two alpha-galactosidase mutants (Q279E and R301Q) found in an atypical variant of Fabry disease. Biochim Biophys Acta 1501 : 227–35.

9. SimsK, PoliteiJ, BanikazemiM, LeeP (2009) Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 40 : 788–94.

10. SachdevB, TakenakaT, TeraguchiH, TeiC, LeeP, et al. (2002) Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105 : 1407–11.

11. EngCM, Resnick-SilvermanLA, NiehausDJ, AstrinKH, DesnickRJ (1993) Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease. Am J Hum Genet 53 : 1186–97.

12. TopalogluAK, AshleyGA, TongB, ShabbeerJ, AstrinKH, et al. (1999) Twenty Novel Mutations in the a-Galactosidase A Gene Causing Fabry Disease. Mol Med 5 : 806–811.

13. BrounsR, ThijsV, EyskensF, Van den BroeckM, BelachewS, et al. (2010) Belgian Fabry Study: Prevalence of Fabry Disease in a Cohort of 1000 Young Patients with Cerebrovascular Disease. Stroke 41 : 863–8.

14. FroissartR, GuffonN, VanierMT, DesnickRJ, MaireI (2003) Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab 80 : 307–14.

15. YasudaM, ShabbeerJ, BensonSD, MaireI, BurnettRM, et al. (2003) Fabry Disease: Characterization of a-Galactosidase A Double Mutations and the D313Y Plasma Enzyme Pseudodeficiency Allele. Hum Mutat 22 : 486–492.

16. BaptistaMV, FerreiraS, Pinho-E-MeloT, CarvalhoM, CruzVT, et al. (2010) Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study–screening genetic conditions in Portuguese young stroke patients. Stroke 41 : 431–6.

17. LinthorstGE, PoorthuisBJ, HollakCE (2008) Enzyme Activity for Determination of Presence of Fabry Disease in Women Results in 40% False-Negative Results. J Am Coll Cardiol 51 : 2082; author reply 2082–3.

18. AertsJM, GroenerJE, KuiperS, Donker-KoopmanWE, StrijlandA, et al. (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 105 : 2812–7.

19. Sanchez-NiñoMD, SanzAB, CarrascoS, SaleemMA, MathiesonPW, et al. (2011) Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant 26 : 1797–802.

20. RombachSM, DekkerN, BouwmanMG, LinthorstGE, ZwindermanAH, et al. (2010) Plasma globotriaosylsphingosine: Diagnostic value and relation to clinical manifestations of Fabry disease. Biochem Biophys Acta 1802 : 741–8.

21. ShimotoriM, MaruyamaH, NakamuraG, SuyamaT, SakamotoF, et al. (2008) Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone. Hum Mutat 29 : 331.

22. AltarescuGM, GoldfarbLG, ParkKY, KaneskiC, JeffriesN, et al. (2001) Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease. Clin Genet 60 : 46–51.

23. GarmanSC, GarbocziDN (2004) The Molecular Defect Leading to Fabry Disease: Structure of Human α-Galactosidase. J Mol Biol 337 : 319–335.

24. MatsuzawaF, AikawaS, DoiH, OkumiyaT, SakurabaH (2005) Fabry disease: correlation between structural changes in α-galactosidase, and clinical and biochemical phenotypes. Hum Genet 117 : 317–328.

25. SaitoS, OhnoK, SeseJ, SugawaraK, SakurabaH (2010) Prediction of the clinical phenotype of Fabry disease based on protein sequential and structural information. J Hum Genet 55 : 175–8.

26. AndreottiG, GuarradinoMR, CammisaM, CorreraA, CubellisMV (2010) Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study. Orphanet J Rare Dis 5 : 36.

27. FiloniC, CaciottiA, CarraresiL, CavicchiC, PariniR, et al. (2010) Functional studies of new GLA gene mutations leading to conformational Fabry disease. Biochim Biophys Acta 1802 : 247–52.

28. ShinSH, Kluepfel-StahlS, CooneyAM, KaneskiCR, QuirkJM, et al. (2008) Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone. Pharmacogenet Genomics 18 : 773–80.

29. BenjaminER, FlanaganJJ, SchillingA, ChangHH, AgarwalL, et al. (2009) The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines. J Inherit Metab Dis 32 : 424–40.

30. WuX, KatzE, Della ValleMC, MascioliK, FlanaganJJ, et al. (2011) A Pharmacogenetic Approach to Identify Mutant Forms of α-Galactosidase A that Respond to a Pharmacological Chaperon for Fabry Disease. Hum Mutat 32 : 965–77.

31. AdzhubeiIA, SchmidtS, PeshkinL, RamenskyVE, GerasimovaA, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7 : 248–9.

32. Desnick RJ, Ioannou YA, Eng CM (2001) The metabolic and molecular basis of inherited disease, ed 8, (New York, USA, McGraw-Hill), pp. 3733–3774.

33. GarmanSC (2007) Structure–function relationships in α-galactosidase A. Acta Paediatrica (Suppl 96): 6–16.

34. van BreemenMJ, RombachSM, DekkerN, PoorthuisBJ, LinthorstGE, et al. (2011) Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta 1812 : 70–6.

35. NiemannM, RolfsA, GieseA, MascherH, BreunigF, ErtlG, WannerC, WeidemannF (2013) Lyso-Gb3 Indicates that the Alpha-Galactosidase A Mutation D313Y is not Clinically Relevant for Fabry Disease. JIMD Rep 7 : 99–102.

36. LukasJ, TorrasJ, NavarroI, GieseA-K, BöttcherT, et al. (2012) Broad spectrum of Fabry disease manifestation in an extended Spanish family with a new deletion in the GLA gene. Clin Kidney J 5 : 395–400.

37. SakurabaH, OshimaA, FukuharaY, ShimmotoM, NagaoY, et al. (1990) Identification of point mutations in the a-Galactosidase A Gene in Classical and Atypical hemizygotes with Fabry Disease. Am J Hum Genet 47 : 784–789.

38. FanJQ, IshiiS (2003) Cell-Based Screening of Active-Site Specific Chaperone for the Treatment of Fabry Disease. Methods Enzymol 363 : 412–420.

39. EngCM, AshleyGA, BurgertTS, EnriquezAL, D'SouzaM, et al. (1997) Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med 3 : 174.

40. DesnickRJ, AllenKY, DesnickSJ, RamanMK, BernlohrRW, et al. (1973) Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med 81 : 157–71.

41. BeutlerE, KuhlW (1972) Purification and Properties of Human α-Galactosidases. J Biol Chem 217 : 7195–7200.